Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17433720 | 0.83 | OPRD1 (0.57) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL20522865 | 0.83 | OPRD1 (0.57) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL20522864 | 0.83 | OPRD1 (0.57) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL17433745 | 0.83 | PTPN1 (0.53) | — | |
| SCHEMBL23361203 | 0.82 | POLB (0.50) | SRD5A2AGTR2OPRM1OPRD1OPRK1 | |
| SCHEMBL20720152 | 0.82 | OPRD1 (0.47) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL9849102 | 0.82 | POLB (0.50) | SRD5A2AGTR2OPRM1OPRD1OPRK1 | |
| SCHEMBL7156807 | 0.82 | OPRD1 (0.47) | AGTR2OPRM1OPRD1OPRK1ACE | |
| SCHEMBL8908771 | 0.79 | ACE (0.61) | ALDH1A1AGTR2ACEPOLBTDP1 | |
| SCHEMBL3840630 | 0.79 | ACE (0.61) | ALDH1A1AGTR2ACEPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975023-B1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2975023-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | Astellas Pharma Inc. (JP) | 2016-01-20 | — | — | EP | disclosed |
| CN-105051008-A | Guanidinobenzoic acid ester compound | ASTELLAS PHARMA INC | 2015-11-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | SERPINB1, REN, SPINT2 | ALDH1A1 1931/4885SRD5A2 3449/4885AGTR2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.